Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer
MIAMI BEACH — After a bumpy start, CDK4/6 inhibitors have started to gain traction in early hormone receptor (HR)-positive/HER2-negative breast cancer, according to recent data. Two negative phase III trials of palbociclib (Ibrance) questioned whether the transformative impact of CDK4/6 inhibition in advanced HR+/HER2- breast cancer would carry over into early disease. More recently, the […]